Antibiotic Susceptibility Pattern of Carbapenem Resistant Acinetobacter Baumannii Isolated from Clinical Specimen

Abstract

Objective: To determine the antibiotic susceptibility pattern of Carbapenem-resistant Acinetobacter baumannii isolated from the different clinical samples.
Study Design: It was a cross-sectional study.
Place and Duration of Study: Department of Microbiology, Khyber Medical University, and the Department of Microbiology, Armed Forces Institute of Pathology (AFIP) from January 2024 to December 2024.
Materials and Methods: After obtaining ethical approval, Various samples from the intensive care units and wards were collected. It included pus, tissue, non-directed bronchial lavage, blood, bronchoalveolar lavage, sputum, fluid, urine, nasopharyngeal swab, drain, bone, and Cerebrospinal fluid, which were processed in the laboratory. All the samples were inoculated on appropriate culture media, and the bacteria were identified by using Gram stain, motility, colony morphology, and biochemical tests. Antibiotic susceptibility was performed by using the Kirby disc diffusion method according to the Clinical and Laboratory Standards Institute (CLSI 2024). Isolates showing resistance or intermediate sensitivity to meropenem and imipenem were considered resistant. Susceptibility pattern of the rest of the antibiotics was noted according to CLSI 2024. SPSS version 26 was used for the data analysis.
Result: Out of 57 Carbapenem-resistant Acinetobacter baumannii 52 (91.2%) were sensitive to minocycline, 39(68.4%) were sensitive to tigecycline, 4(7%) to gentamicin, 3(5.2%) were sensitive to cefepime, 2(3.5%) to ceftazidime, 1(1.8%) to levofloxacin, tazo-pipracillin and ceftriaxone and showed no sensitivity to amikacin, ciprofloxacin and ampicillin-sulbactam. Tetracycline was tested in urine samples, and Carbapenem-resistant Acinetobacter baumannii showed 100% sensitivity towards it.
Conclusion: Carbapenem-resistant Acinetobacter baumannii showed very low susceptibility to maximum antibiotics. The highest was towards minocycline.